Literature DB >> 35219768

Assessing the Impact of Decision Aid Use on Post Prostatectomy Patient Reported Outcomes.

Giulia I Lane1, Ji Qi2, Ajith Dupati3, Stephanie Ferrante2, Rodney L Dunn2, Roshan Paudel4, Daniela Wittmann2, Lauren P Wallner5, Donna L Berry6, Chad Ellimoottil2, James E Montie2, J Quentin Clemens2.   

Abstract

OBJECTIVE: To evaluate whether completing a decision aid, Personal Patient Profile - Prostate (P3P), prior to prostatectomy, affects self-reported bother from post-prostatectomy urinary incontinence and erectile dysfunction.
MATERIALS AND METHODS: This retrospective analysis included data from men with newly diagnosed clinically localized, very low to intermediate risk prostate cancer who elected for prostatectomy within the Michigan Urological Surgery Improvement Collaborative between 2018-2021. Multivariable logistic regression models were used to estimate the association between P3P use and bother from post prostatectomy erectile dysfunction and urinary incontinence as measured by the Expanded Prostate Cancer Index Composite (EPIC-26).
RESULTS: Among the 3987 patients included, 7% used P3P (n = 266). Men who used P3P reported significantly less bother from erectile dysfunction at 6 months vs non-users (aOR 0.42 [95% CI 0.27-0.66]). At 12 months, the effect of P3P on bother from erectile dysfunction was not statistically significant (aOR 0.62 [95% CI 0.37-1.03]). Men who used P3P did not have a statistically significant difference in bother from urinary incontinence (3-month: aOR 0.56 [95% CI 0.30-1.06]; 6-month; aOR 0.79 [95% CI 0.31-1.97]).
CONCLUSION: Within the stated limitations of this study, we find that use of a decision aid for localized prostate cancer was associated with decreased odds of men being bothered from sexual dysfunction but not urinary incontinence at 6 months post prostatectomy. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2022        PMID: 35219768      PMCID: PMC9296586          DOI: 10.1016/j.urology.2022.02.008

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.633


  20 in total

1.  Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men.

Authors:  Aruna V Sarma; Steven J Jacobsen; Cynthia J Girman; Debra J Jacobson; Rosebud O Roberts; Thomas Rhodes; Michael Lieber
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

2.  Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy.

Authors:  Timothy P Pearman; Jennifer L Beaumont; Daniel Mroczek; Mary O'Connor; David Cella
Journal:  Cancer       Date:  2017-11-13       Impact factor: 6.860

3.  Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial.

Authors:  Donna L Berry; Fangxin Hong; Traci M Blonquist; Barbara Halpenny; Christopher P Filson; Viraj A Master; Martin G Sanda; Peter Chang; Gary W Chien; Randy A Jones; Tracey L Krupski; Seth Wolpin; Leslie Wilson; Julia H Hayes; Quoc-Dien Trinh; Mitchell Sokoloff; Prabhakara Somayaji
Journal:  J Urol       Date:  2017-07-25       Impact factor: 7.450

4.  Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy.

Authors:  Zvi Symon; Stephanie Daignault; Rachel Symon; Rodney L Dunn; Martin G Sanda; Howard M Sandler
Journal:  Urology       Date:  2006-12-04       Impact factor: 2.649

5.  Longitudinal regret and information satisfaction after deciding on treatment for localized prostate cancer with or without a decision aid. Results at one-year follow-up in the PCPCC trial.

Authors:  Maarten Cuypers; Romy E D Lamers; Paul J M Kil; Lonneke V van de Poll-Franse; Marieke de Vries
Journal:  Patient Educ Couns       Date:  2018-10-04

6.  Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer.

Authors:  David J Einstein; Dattatraya Patil; Jonathan Chipman; Meredith M Regan; Kyle Davis; Catrina M Crociani; Andrew A Wagner; Martin G Sanda; Peter Chang
Journal:  Urology       Date:  2019-02-18       Impact factor: 2.649

7.  Preparedness for side effects and bother in symptomatic men after radical prostatectomy in a prospective, non-randomized trial, LAPPRO.

Authors:  Maryam Derogar; Hanna Dahlstrand; Stefan Carlsson; Anders Bjartell; Jonas Hugosson; Elin Axén; Eva Johansson; Mikael Lagerkvist; Tommy Nyberg; Johan Stranne; Thordis Thorsteinsdottir; Anna Wallerstedt; Eva Haglind; Peter Wiklund; Gunnar Steineck
Journal:  Acta Oncol       Date:  2016-08-16       Impact factor: 4.089

8.  Impact of a web-based treatment decision aid for early-stage prostate cancer on shared decision-making and health outcomes: study protocol for a randomized controlled trial.

Authors:  Maarten Cuypers; Romy E D Lamers; Paul J M Kil; Lonneke V van de Poll-Franse; Marieke de Vries
Journal:  Trials       Date:  2015-05-27       Impact factor: 2.279

9.  Relationship of symptom severity and bother in individuals seeking care for lower urinary tract symptoms.

Authors:  Nnenaya Agochukwu-Mmonu; Jonathan B Wiseman; Abigail R Smith; Margaret E Helmuth; Aruna V Sarma; Anne P Cameron; Cindy L Amundsen; Kathryn E Flynn; David Cella; Kevin P Weinfurt; Ziya Kirkali; J Quentin Clemens
Journal:  Neurourol Urodyn       Date:  2020-08-06       Impact factor: 2.696

10.  Evaluation of Patient- and Surgeon-Specific Variations in Patient-Reported Urinary Outcomes 3 Months After Radical Prostatectomy From a Statewide Improvement Collaborative.

Authors:  Gregory B Auffenberg; Ji Qi; Rodney L Dunn; Susan Linsell; Tae Kim; David C Miller; Jeffrey Tosoian; Richard Sarle; William K Johnston; Eduardo Kleer; Khurshid R Ghani; James Montie; James Peabody
Journal:  JAMA Surg       Date:  2021-03-10       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.